Medpace Holdings Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Medpace Holdings Inc is far larger — about 9.5× Vir Biotechnology Inc. Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vir Biotechnology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| MEDP | VIR | |
|---|---|---|
Market Cap | $17.02B | $1.80B |
Volume | 155,250 | 1,782,836 |
Sector | Health | Health |
52-Week High | $630.19 | $11.78 |
52-Week Low | $393.42 | $5.12 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.63B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →